Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Swedish Orphan Biovitrum

388.60 SEK

-1.72 %

Less than 1K followers

SOBI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.72 %
+15.31 %
+16.77 %
+13.96 %
+41.31 %
+23.13 %
+69.23 %
+188.23 %
+714.36 %

Swedish Orphan Biovitrum operates in the pharmaceutical industry and focuses on the development and distribution of medicines for rare diseases. The company's products are aimed at healthcare institutions and patients with specific medical needs. The business is global with a main presence in Europe, North America and Asia. Swedish Orphan Biovitrum was founded in 1939 and is headquartered in Stockholm, Sweden.

Read more
Market cap
138.89B SEK
Turnover
126.75M SEK
Revenue
28.24B
EBIT %
3.07 %
P/E
279.57
Dividend yield-%
-
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28/4
2026

Interim report Q1'26

6/5
2026

General meeting '26

16/7
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Regulatory press release2/18/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

Swedish Orphan Biovitrum
Regulatory press release2/18/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobis kapitalmarknadsdag 2026: Bringing brillant ideas to life - med ambitionen att nå 55 miljarder kronor till 2030 inleder vi nästa kapitel

Swedish Orphan Biovitrum
Regulatory press release2/5/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobi publicerar delårsrapport för fjärde kvartalet och bokslutskommuniké för 2025: Året avslutas med betydande tillväxt och strategiska framsteg

Swedish Orphan Biovitrum

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2/5/2026, 7:00 AM

Swedish Orphan Biovitrum AB: Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress

Swedish Orphan Biovitrum
Regulatory press release1/15/2026, 11:30 AM

Swedish Orphan Biovitrum AB: Sobis intäkter och justerade EBITA-marginal för helåret 2025 överstiger tidigare prognos

Swedish Orphan Biovitrum
Regulatory press release1/15/2026, 11:30 AM

Swedish Orphan Biovitrum AB: Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook

Swedish Orphan Biovitrum
Regulatory press release1/7/2026, 5:00 PM

Swedish Orphan Biovitrum AB: Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data

Swedish Orphan Biovitrum
Regulatory press release1/7/2026, 5:00 PM

Swedish Orphan Biovitrum AB: Sobi vidareutvecklar Gamifant® (emapalumab) vid gammainterferon-driven sepsis (IDS) baserat på topline-data från EMBRACE

Swedish Orphan Biovitrum
Regulatory press release12/13/2025, 4:00 PM

Swedish Orphan Biovitrum AB: Sobi förvärvar Arthrosi Therapeutics och stärker sin pipeline med potentiell behandling av gikt

Swedish Orphan Biovitrum
Regulatory press release12/13/2025, 4:00 PM

Swedish Orphan Biovitrum AB: Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

Swedish Orphan Biovitrum
Regulatory press release10/21/2025, 11:00 AM

Swedish Orphan Biovitrum AB: Förändring i Sobis styrelse

Swedish Orphan Biovitrum
Regulatory press release10/21/2025, 11:00 AM

Swedish Orphan Biovitrum AB: Change in the Sobi Board of Directors

Swedish Orphan Biovitrum
Regulatory press release10/20/2025, 6:00 AM

Swedish Orphan Biovitrum AB: Sobi Q3 2025 report: Accelerated growth and portfolio momentum

Swedish Orphan Biovitrum
Regulatory press release10/20/2025, 6:00 AM

Swedish Orphan Biovitrum AB: Sobi publicerar delårsrapport för tredje kvartalet 2025: Accelererad tillväxt och momentum i portföljen

Swedish Orphan Biovitrum
Regulatory press release10/19/2025, 6:30 PM

Swedish Orphan Biovitrum AB: Sobi meddelar reviderade helårsutsikter och tidigarelägger publiceringen av delårsrapporten för tredje kvartalet 2025

Swedish Orphan Biovitrum
Regulatory press release10/19/2025, 6:30 PM

Swedish Orphan Biovitrum AB: Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report

Swedish Orphan Biovitrum
Regulatory press release9/30/2025, 6:00 AM

Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi

Swedish Orphan Biovitrum
Regulatory press release9/30/2025, 6:00 AM

Swedish Orphan Biovitrum AB: Ändring av antalet aktier och röster i Sobi

Swedish Orphan Biovitrum
Regulatory press release8/29/2025, 6:00 AM

Swedish Orphan Biovitrum AB: Ändring av antalet aktier och röster i Sobi

Swedish Orphan Biovitrum
Regulatory press release8/29/2025, 6:00 AM

Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi

Swedish Orphan Biovitrum
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.